STOCK TITAN

[8-K/A] SRX Health Solutions, Inc. Amends Material Event Report

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
8-K/A
Rhea-AI Filing Summary

LuxUrban Hotels Inc. (Nasdaq: LUXHP) has filed Form 25 with Nasdaq, initiating the removal of its Common Stock and 13.00% Series A Cumulative Redeemable Preferred Stock from listing and registration under Section 12(b) of the Securities Exchange Act of 1934.

The filing was signed by Nasdaq on 11 July 2025, indicating that the exchange believes it has met all regulatory requirements to delist the securities. The notice references Rule 12d2-2(b), which covers exchange-initiated delistings, suggesting the action was driven by Nasdaq rather than a voluntary request from the issuer. Once the Form 25 becomes effective (typically ten days after filing), the securities will no longer be traded on Nasdaq and their registration under the Exchange Act will be withdrawn 90 days thereafter, unless the company takes alternative steps.

Key implications for investors:

  • Loss of Nasdaq listing often results in reduced liquidity, wider bid-ask spreads, and potential migration to over-the-counter markets.
  • Delisting may trigger covenants in debt or preferred instruments and can affect institutional ownership thresholds tied to exchange-listed status.
  • No financial performance data or explanation for the delisting is provided in this filing; investors must look for additional disclosures or 8-K filings for context.

LuxUrban Hotels Inc. (Nasdaq: LUXHP) ha presentato il Modulo 25 presso il Nasdaq, avviando la rimozione delle sue azioni ordinarie e delle azioni privilegiate rimborsabili cumulative Serie A al 13,00% dalla quotazione e dalla registrazione ai sensi della Sezione 12(b) del Securities Exchange Act del 1934.

La presentazione è stata firmata dal Nasdaq l'11 luglio 2025, indicando che la borsa ritiene di aver soddisfatto tutti i requisiti normativi per la cancellazione delle azioni. L’avviso fa riferimento alla Regola 12d2-2(b), che riguarda le cancellazioni avviate dall'exchange, suggerendo che l’azione sia stata intrapresa dal Nasdaq piuttosto che su richiesta volontaria dell’emittente. Una volta che il Modulo 25 diventa efficace (di solito dieci giorni dopo la presentazione), i titoli non saranno più negoziati sul Nasdaq e la loro registrazione ai sensi dell’Exchange Act sarà ritirata dopo 90 giorni, a meno che la società non intraprenda azioni alternative.

Principali implicazioni per gli investitori:

  • La perdita della quotazione al Nasdaq comporta spesso una riduzione della liquidità, spread denaro-lettera più ampi e possibile migrazione ai mercati over-the-counter.
  • La cancellazione può attivare clausole in obbligazioni o strumenti privilegiati e influire sulle soglie di proprietà istituzionale legate allo status di quotazione in borsa.
  • La documentazione non fornisce dati sulle performance finanziarie né spiegazioni per la cancellazione; gli investitori devono cercare ulteriori comunicazioni o documenti 8-K per maggiori dettagli.

LuxUrban Hotels Inc. (Nasdaq: LUXHP) ha presentado el Formulario 25 ante Nasdaq, iniciando la eliminación de sus acciones comunes y acciones preferentes redimibles acumulativas Serie A al 13.00% de la cotización y registro bajo la Sección 12(b) del Securities Exchange Act de 1934.

La presentación fue firmada por Nasdaq el 11 de julio de 2025, indicando que la bolsa considera que se han cumplido todos los requisitos regulatorios para la exclusión de los valores. El aviso hace referencia a la Regla 12d2-2(b), que cubre exclusiones iniciadas por la bolsa, sugiriendo que la acción fue impulsada por Nasdaq y no por una solicitud voluntaria del emisor. Una vez que el Formulario 25 entre en vigor (normalmente diez días después de la presentación), los valores dejarán de cotizar en Nasdaq y su registro bajo el Exchange Act será retirado 90 días después, a menos que la empresa tome medidas alternativas.

Implicaciones clave para los inversores:

  • La pérdida de la cotización en Nasdaq suele resultar en menor liquidez, mayores diferenciales de compra-venta y posible migración a mercados extrabursátiles.
  • La exclusión puede activar cláusulas en instrumentos de deuda o preferentes y afectar los umbrales de propiedad institucional vinculados al estatus de cotización en bolsa.
  • No se proporcionan datos financieros ni explicación para la exclusión en esta presentación; los inversores deben buscar divulgaciones adicionales o presentaciones 8-K para contexto.

LuxUrban Hotels Inc. (나스닥: LUXHP)는 나스닥에 Form 25를 제출하여 보통주 및 13.00% 시리즈 A 누적 상환 우선주를 증권거래법 1934년 법 제12(b)조에 따른 상장 및 등록에서 제외하는 절차를 시작했습니다.

이 제출서는 2025년 7월 11일 나스닥이 서명했으며, 거래소가 상장폐지 규제 요건을 모두 충족했다고 판단했음을 나타냅니다. 통지서에는 거래소 주도 상장폐지를 다루는 규칙 12d2-2(b)가 언급되어 있어, 발행자의 자발적 요청이 아닌 나스닥 주도의 조치임을 시사합니다. Form 25가 효력을 발생하면(일반적으로 제출 후 10일), 해당 증권은 나스닥에서 더 이상 거래되지 않으며, 90일 후에는 증권거래법에 따른 등록이 철회됩니다. 단, 회사가 다른 조치를 취하지 않는 한 해당됩니다.

투자자에게 중요한 영향:

  • 나스닥 상장 상실은 유동성 감소, 매도-매수 스프레드 확대, 장외시장으로의 이전 가능성을 초래합니다.
  • 상장폐지는 부채 또는 우선주 관련 계약 조건을 발동할 수 있으며, 상장 상태에 따른 기관 투자자 소유 비율에도 영향을 미칠 수 있습니다.
  • 이번 제출서에는 재무 성과 데이터나 상장폐지 사유가 포함되어 있지 않으므로, 투자자는 추가 공시나 8-K 보고서를 통해 상황을 확인해야 합니다.

LuxUrban Hotels Inc. (Nasdaq : LUXHP) a déposé le Formulaire 25 auprès de Nasdaq, lançant ainsi la procédure de retrait de ses actions ordinaires et de ses actions privilégiées cumulatives remboursables Série A à 13,00 % de la cotation et de l'enregistrement en vertu de la Section 12(b) du Securities Exchange Act de 1934.

Le dépôt a été signé par Nasdaq le 11 juillet 2025, indiquant que la bourse estime avoir rempli toutes les exigences réglementaires pour la radiation des titres. L’avis fait référence à la Règle 12d2-2(b), qui couvre les radiations initiées par la bourse, suggérant que l’action a été prise par Nasdaq et non à la demande volontaire de l’émetteur. Une fois que le Formulaire 25 devient effectif (généralement dix jours après le dépôt), les titres ne seront plus négociés sur Nasdaq et leur enregistrement en vertu de l’Exchange Act sera retiré 90 jours plus tard, sauf si la société prend des mesures alternatives.

Principales implications pour les investisseurs :

  • La perte de la cotation Nasdaq entraîne souvent une liquidité réduite, des écarts acheteur-vendeur plus larges et une possible migration vers les marchés de gré à gré.
  • La radiation peut déclencher des clauses dans les instruments de dette ou privilégiés et affecter les seuils de détention institutionnelle liés au statut de cotation.
  • Aucune donnée financière ni explication sur la radiation n’est fournie dans ce dépôt ; les investisseurs doivent rechercher des divulgations supplémentaires ou des dépôts 8-K pour plus de contexte.

LuxUrban Hotels Inc. (Nasdaq: LUXHP) hat bei Nasdaq das Formular 25 eingereicht und damit die Entfernung seiner Stammaktien sowie der 13,00% Series A kumulativen rückzahlbaren Vorzugsaktien von der Notierung und Registrierung gemäß Abschnitt 12(b) des Securities Exchange Act von 1934 eingeleitet.

Die Einreichung wurde am 11. Juli 2025 von Nasdaq unterzeichnet, was darauf hinweist, dass die Börse der Ansicht ist, alle regulatorischen Anforderungen für die Delistung der Wertpapiere erfüllt zu haben. Die Mitteilung verweist auf Regel 12d2-2(b), die von der Börse initiierte Delistings abdeckt, was darauf hindeutet, dass die Maßnahme von Nasdaq ausgegangen ist und nicht auf einen freiwilligen Antrag des Emittenten. Sobald das Formular 25 wirksam wird (in der Regel zehn Tage nach Einreichung), werden die Wertpapiere nicht mehr an Nasdaq gehandelt und ihre Registrierung unter dem Exchange Act wird 90 Tage später zurückgezogen, sofern das Unternehmen keine alternativen Schritte unternimmt.

Wesentliche Auswirkungen für Investoren:

  • Der Verlust der Nasdaq-Notierung führt häufig zu geringerer Liquidität, größeren Geld-Brief-Spannen und einer möglichen Verlagerung in den außerbörslichen Handel.
  • Die Delistung kann Vertragsklauseln bei Schuldtiteln oder Vorzugsaktien auslösen und institutionelle Besitzschwellen beeinflussen, die an den Börsenstatus gebunden sind.
  • Die Einreichung enthält keine Finanzdaten oder Erklärungen zur Delistung; Investoren sollten weitere Offenlegungen oder 8-K-Meldungen zur Einordnung suchen.
Positive
  • None.
Negative
  • Loss of Nasdaq listing reduces liquidity and may pressure valuation.
  • Exchange-initiated delisting implies compliance or financial deficiencies, elevating risk perception.
  • Preferred shareholders face increased trading friction and potential covenant breaches.

Insights

TL;DR: Nasdaq is delisting LuxUrban’s common and Series A preferred shares; liquidity and perception risks rise.

The Form 25 confirms that LuxUrban Hotels will lose its Nasdaq listing for both its common equity and 13% Series A preferred. Because the exchange checked Rule 12d2-2(b), the action appears exchange-initiated, implying compliance or financial deficiencies. Delisting typically compresses valuation multiples as sell-side coverage, institutional ownership, and trading volumes drop. The preferred shares’ high 13% coupon already signals elevated credit risk; losing an exchange listing further narrows the investor pool and could impact future capital-raising capability. Investors should monitor subsequent company statements or 8-K filings for root causes, any appeal process, or plans to seek an alternative listing such as NYSE American or OTCQX.

TL;DR: Exchange-initiated delisting reflects governance/compliance shortcomings and heightens oversight concerns.

When Nasdaq files Form 25 under Rule 12d2-2(b), it typically follows unresolved deficiencies—late filings, minimum bid price violations, or corporate governance lapses. The absence of issuer-driven Rule 12d2-2(c) language suggests LuxUrban did not voluntarily delist, which is a red flag for governance practices. Stakeholders should scrutinize board actions, disclosure timeliness, and auditor communications for potential material weaknesses. Delisting can limit shareholder protections afforded by exchange rules, shifting reliance to state law and OTC market standards. The impact is materially negative until the issuer restores compliance or secures a new listing.

LuxUrban Hotels Inc. (Nasdaq: LUXHP) ha presentato il Modulo 25 presso il Nasdaq, avviando la rimozione delle sue azioni ordinarie e delle azioni privilegiate rimborsabili cumulative Serie A al 13,00% dalla quotazione e dalla registrazione ai sensi della Sezione 12(b) del Securities Exchange Act del 1934.

La presentazione è stata firmata dal Nasdaq l'11 luglio 2025, indicando che la borsa ritiene di aver soddisfatto tutti i requisiti normativi per la cancellazione delle azioni. L’avviso fa riferimento alla Regola 12d2-2(b), che riguarda le cancellazioni avviate dall'exchange, suggerendo che l’azione sia stata intrapresa dal Nasdaq piuttosto che su richiesta volontaria dell’emittente. Una volta che il Modulo 25 diventa efficace (di solito dieci giorni dopo la presentazione), i titoli non saranno più negoziati sul Nasdaq e la loro registrazione ai sensi dell’Exchange Act sarà ritirata dopo 90 giorni, a meno che la società non intraprenda azioni alternative.

Principali implicazioni per gli investitori:

  • La perdita della quotazione al Nasdaq comporta spesso una riduzione della liquidità, spread denaro-lettera più ampi e possibile migrazione ai mercati over-the-counter.
  • La cancellazione può attivare clausole in obbligazioni o strumenti privilegiati e influire sulle soglie di proprietà istituzionale legate allo status di quotazione in borsa.
  • La documentazione non fornisce dati sulle performance finanziarie né spiegazioni per la cancellazione; gli investitori devono cercare ulteriori comunicazioni o documenti 8-K per maggiori dettagli.

LuxUrban Hotels Inc. (Nasdaq: LUXHP) ha presentado el Formulario 25 ante Nasdaq, iniciando la eliminación de sus acciones comunes y acciones preferentes redimibles acumulativas Serie A al 13.00% de la cotización y registro bajo la Sección 12(b) del Securities Exchange Act de 1934.

La presentación fue firmada por Nasdaq el 11 de julio de 2025, indicando que la bolsa considera que se han cumplido todos los requisitos regulatorios para la exclusión de los valores. El aviso hace referencia a la Regla 12d2-2(b), que cubre exclusiones iniciadas por la bolsa, sugiriendo que la acción fue impulsada por Nasdaq y no por una solicitud voluntaria del emisor. Una vez que el Formulario 25 entre en vigor (normalmente diez días después de la presentación), los valores dejarán de cotizar en Nasdaq y su registro bajo el Exchange Act será retirado 90 días después, a menos que la empresa tome medidas alternativas.

Implicaciones clave para los inversores:

  • La pérdida de la cotización en Nasdaq suele resultar en menor liquidez, mayores diferenciales de compra-venta y posible migración a mercados extrabursátiles.
  • La exclusión puede activar cláusulas en instrumentos de deuda o preferentes y afectar los umbrales de propiedad institucional vinculados al estatus de cotización en bolsa.
  • No se proporcionan datos financieros ni explicación para la exclusión en esta presentación; los inversores deben buscar divulgaciones adicionales o presentaciones 8-K para contexto.

LuxUrban Hotels Inc. (나스닥: LUXHP)는 나스닥에 Form 25를 제출하여 보통주 및 13.00% 시리즈 A 누적 상환 우선주를 증권거래법 1934년 법 제12(b)조에 따른 상장 및 등록에서 제외하는 절차를 시작했습니다.

이 제출서는 2025년 7월 11일 나스닥이 서명했으며, 거래소가 상장폐지 규제 요건을 모두 충족했다고 판단했음을 나타냅니다. 통지서에는 거래소 주도 상장폐지를 다루는 규칙 12d2-2(b)가 언급되어 있어, 발행자의 자발적 요청이 아닌 나스닥 주도의 조치임을 시사합니다. Form 25가 효력을 발생하면(일반적으로 제출 후 10일), 해당 증권은 나스닥에서 더 이상 거래되지 않으며, 90일 후에는 증권거래법에 따른 등록이 철회됩니다. 단, 회사가 다른 조치를 취하지 않는 한 해당됩니다.

투자자에게 중요한 영향:

  • 나스닥 상장 상실은 유동성 감소, 매도-매수 스프레드 확대, 장외시장으로의 이전 가능성을 초래합니다.
  • 상장폐지는 부채 또는 우선주 관련 계약 조건을 발동할 수 있으며, 상장 상태에 따른 기관 투자자 소유 비율에도 영향을 미칠 수 있습니다.
  • 이번 제출서에는 재무 성과 데이터나 상장폐지 사유가 포함되어 있지 않으므로, 투자자는 추가 공시나 8-K 보고서를 통해 상황을 확인해야 합니다.

LuxUrban Hotels Inc. (Nasdaq : LUXHP) a déposé le Formulaire 25 auprès de Nasdaq, lançant ainsi la procédure de retrait de ses actions ordinaires et de ses actions privilégiées cumulatives remboursables Série A à 13,00 % de la cotation et de l'enregistrement en vertu de la Section 12(b) du Securities Exchange Act de 1934.

Le dépôt a été signé par Nasdaq le 11 juillet 2025, indiquant que la bourse estime avoir rempli toutes les exigences réglementaires pour la radiation des titres. L’avis fait référence à la Règle 12d2-2(b), qui couvre les radiations initiées par la bourse, suggérant que l’action a été prise par Nasdaq et non à la demande volontaire de l’émetteur. Une fois que le Formulaire 25 devient effectif (généralement dix jours après le dépôt), les titres ne seront plus négociés sur Nasdaq et leur enregistrement en vertu de l’Exchange Act sera retiré 90 jours plus tard, sauf si la société prend des mesures alternatives.

Principales implications pour les investisseurs :

  • La perte de la cotation Nasdaq entraîne souvent une liquidité réduite, des écarts acheteur-vendeur plus larges et une possible migration vers les marchés de gré à gré.
  • La radiation peut déclencher des clauses dans les instruments de dette ou privilégiés et affecter les seuils de détention institutionnelle liés au statut de cotation.
  • Aucune donnée financière ni explication sur la radiation n’est fournie dans ce dépôt ; les investisseurs doivent rechercher des divulgations supplémentaires ou des dépôts 8-K pour plus de contexte.

LuxUrban Hotels Inc. (Nasdaq: LUXHP) hat bei Nasdaq das Formular 25 eingereicht und damit die Entfernung seiner Stammaktien sowie der 13,00% Series A kumulativen rückzahlbaren Vorzugsaktien von der Notierung und Registrierung gemäß Abschnitt 12(b) des Securities Exchange Act von 1934 eingeleitet.

Die Einreichung wurde am 11. Juli 2025 von Nasdaq unterzeichnet, was darauf hinweist, dass die Börse der Ansicht ist, alle regulatorischen Anforderungen für die Delistung der Wertpapiere erfüllt zu haben. Die Mitteilung verweist auf Regel 12d2-2(b), die von der Börse initiierte Delistings abdeckt, was darauf hindeutet, dass die Maßnahme von Nasdaq ausgegangen ist und nicht auf einen freiwilligen Antrag des Emittenten. Sobald das Formular 25 wirksam wird (in der Regel zehn Tage nach Einreichung), werden die Wertpapiere nicht mehr an Nasdaq gehandelt und ihre Registrierung unter dem Exchange Act wird 90 Tage später zurückgezogen, sofern das Unternehmen keine alternativen Schritte unternimmt.

Wesentliche Auswirkungen für Investoren:

  • Der Verlust der Nasdaq-Notierung führt häufig zu geringerer Liquidität, größeren Geld-Brief-Spannen und einer möglichen Verlagerung in den außerbörslichen Handel.
  • Die Delistung kann Vertragsklauseln bei Schuldtiteln oder Vorzugsaktien auslösen und institutionelle Besitzschwellen beeinflussen, die an den Börsenstatus gebunden sind.
  • Die Einreichung enthält keine Finanzdaten oder Erklärungen zur Delistung; Investoren sollten weitere Offenlegungen oder 8-K-Meldungen zur Einordnung suchen.

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K/A

 

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): April 24, 2025 

 

 

 

SRx Health Solutions, Inc.

(Exact name of Registrant as Specified in its Charter)

 

 

 

Delaware   001-40477   83-4284557
(State or other Jurisdiction   (Commission   (IRS Employer
of Incorporation)   File Number)   Identification No.)

 

12400 Race Track Road

Tampa, Florida 33626

(Address of Principal Executive Offices) (Zip Code)

 

 

 

(Registrant’s Telephone Number, Including Area Code):(212) 896-1254

 

N/A

(Former name or former address, if changed since last report.)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.001 par value share   SRXH   NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Explanatory Note

 

On April 24, 2025 (the “Closing Date”), SRx Health Solutions, Inc., a Delaware corporation (f/k/a Better Choice Company, Inc.) (the “Company” or the “Registrant” or “we”, “us” or “our”) announced that it closed the business combination (the “Business Combination”) by and among the Company, 1000994476 Ontario Inc., an Ontario corporation (“AcquireCo”), 1000994085 Ontario Inc., an Ontario Corporation (“CallCo”) and SRx Health Solutions (Canada), Inc., an Ontario corporation (f/k/a SRx Health Solutions, Inc.) (“SRx Canada”), whereby the Company acquired SRx Canada pursuant to the terms of an Arrangement Agreement and Plan of Arrangement entered into on September 2, 2024, by and among the Company, AcquireCo, CallCo and SRx Canada (the “Arrangement Agreement”). Pursuant to the Arrangement Agreement, on the Closing Date, AcquireCo, an indirect wholly-owned subsidiary of the Company, merged with and into SRx Canada, with SRx Canada remaining as the surviving entity.

 

The Company filed a Current Report on Form 8-K on April 24, 2025 (the “Initial Report”) in which the Company disclosed, among other information, its intention to file the financial statements required by Item 9.01(a) and the pro forma financial information required by Item 9.01(b) as part of an amendment to the Initial Report no later than 71 calendar days after the required filing date of the Initial Report. This Current Report on Form 8-K/A amends the Initial Report to include certain financial statements of the Company and certain pro forma financial information as required by Item 9.01, which are filed as exhibits hereto and are incorporated herein by reference. No disclosure of the text of Item 1.01, Item 2.01, Item 5.01, Item 5.02, Item 5.03, Item 8.01 or Item 9.01(d) of the Initial Report was changed as a result of this Current Report on Form 8-K/A except for the addition of the exhibits listed in Item 9.01(d) of this Current Report on Form 8-K/A.

 

2

 

 

Item 9.01. Financial Statements and Exhibits.

 

(a) Financial Statements of Businesses Acquired.

 

SRx Canada’s consolidated financial statements for the years ended September 30, 2024 and 2023 and related notes are filed as Exhibit 99.1 to this Current Report on Form 8-K/A and are incorporated herein by reference.

 

SRx Canada’s unaudited condensed consolidated financial statements for the three and six months ended March 31, 2025 and 2024 and related notes are filed as Exhibit 99.2 to this Current Report on Form 8-K/A and are incorporated herein by reference.

 

(b) Pro Forma Financial Information.

 

The unaudited pro forma condensed combined financial information of the Company, giving effect to the Business Combination, is filed as Exhibit 99.3 to this Current Report on Form 8-K/A and is incorporated herein by reference.

 

The unaudited pro forma condensed combined financial information and the accompanying notes included in this Current Report on Form 8-K/A has been presented for informational purposes only, as required by the disclosure requirements of Form 8-K, and is not necessarily indicative of the actual financial position or results of operations that the Company would have realized had the companies been combined as of the dates or during the periods presented, nor is it intended to be indicative of any anticipated combined financial position or future results of operations that the Company may achieve after the Business Combination.

 

(d) Exhibits.

 

The following exhibits are included as part of this Current Report on Form 8-K/A:

 

Exhibit No.   Description
     
23.1   Consent of MNP LLP, independent auditors of SRx Health Solutions (Canada), Inc. (f/k/a SRx Health Solutions, Inc.).
99.1   SRx Canada’s consolidated financial statements for the years ended September 30, 2024 and 2023 and related notes.
99.2   SRx Canada’s unaudited condensed consolidated financial statements for the three and six months ended March 31, 2025 and March 31, 2024 and related notes.
99.3   Unaudited pro forma condensed combined financial information and related notes.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

3

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

July 11, 2025 SRx Health Solutions, Inc.
     
  By: /s/ Carolina Martinez
  Name: Carolina Martinez
  Title: Chief Financial Officer

 

4

SRX Health Solutions Inc

NYSE:SRXH

SRXH Rankings

SRXH Latest News

SRXH Latest SEC Filings

SRXH Stock Data

7.16M
10.64M
Beverages
TAMPA